NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX)
LXRX Technical Analysis
5
As on 28th Mar 2025 LXRX STOCK Price closed @ 0.57 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.75 & Strong Sell for SHORT-TERM with Stoploss of 1.19 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LXRXSTOCK Price
Open | 0.65 | Change | Price | % |
High | 0.70 | 1 Day | 0.22 | 62.86 |
Low | 0.51 | 1 Week | 0.21 | 58.33 |
Close | 0.57 | 1 Month | -0.17 | -22.97 |
Volume | 404328778 | 1 Year | -0.50 | -46.73 |
52 Week High 3.58 | 52 Week Low 0.29 |
NASDAQ USA Most Active Stocks
AMRS | 0.14 | 100.00% |
LXRX | 0.57 | 62.86% |
NVDA | 109.67 | -1.58% |
SNSE | 0.51 | 18.60% |
TSLA | 263.55 | -3.51% |
LMDX | 0.02 | 0.00% |
AKTS | 0.04 | 0.00% |
LILM | 0.05 | -79.17% |
PONO | 1.72 | 2.38% |
TELL | 1.00 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
LXRX Daily Charts |
LXRX Intraday Charts |
Whats New @ Bazaartrend |
LXRX Free Analysis |
|
LXRX Important Levels Intraday
RESISTANCE | 0.94 |
RESISTANCE | 0.82 |
RESISTANCE | 0.75 |
RESISTANCE | 0.67 |
SUPPORT | 0.47 |
SUPPORT | 0.39 |
SUPPORT | 0.32 |
SUPPORT | 0.20 |
LXRX Forecast March 2025
4th UP Forecast | 1.78 |
3rd UP Forecast | 1.39 |
2nd UP Forecast | 1.15 |
1st UP Forecast | 0.91 |
1st DOWN Forecast | 0.23 |
2nd DOWN Forecast | -0.01 |
3rd DOWN Forecast | -0.25 |
4th DOWN Forecast | -0.64 |
LXRX Weekly Forecast
4th UP Forecast | 1.40 |
3rd UP Forecast | 1.13 |
2nd UP Forecast | 0.97 |
1st UP Forecast | 0.80 |
1st DOWN Forecast | 0.34 |
2nd DOWN Forecast | 0.17 |
3rd DOWN Forecast | 0.01 |
4th DOWN Forecast | -0.26 |
LXRX Forecast2025
4th UP Forecast | 7.22 |
3rd UP Forecast | 5.09 |
2nd UP Forecast | 3.77 |
1st UP Forecast | 2.45 |
1st DOWN Forecast | -1.31 |
2nd DOWN Forecast | -2.63 |
3rd DOWN Forecast | -3.95 |
4th DOWN Forecast | -6.08 |
Lexicon Pharmaceuticals Inc ( NASDAQ USA Symbol : LXRX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LXRX Other Details
Segment | EQ | |
Market Capital | 762822720.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
LXRX Address
![]() |
LXRX Latest News
LXRX Business Profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Address: 8800 Technology Forest Place, The Woodlands, TX, United States, 77381-1160
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service